← Leaderboards
Aijun Wang
University Of California At Davis
$6,380,053
Attributed
$10,904,382
Total exposure
10
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2017–25$2.5M$1.9M$1.3M$625K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,904,382 · 10
By mechanism
R01$9,468,878 · 6
R21$1,278,504 · 3
R03$157,000 · 1
Top collaborators
- Randy Carney9 shared
- Diana Lee Farmer7 shared
- Cheemeng Tan5 shared
- Soheil Ghiasi2 shared
- Yi Hong2 shared
- Niren Murthy1 shared
- David E. Pleasure1 shared
- Jill Lynn Silverman1 shared
Most similar at University Of California At Davis
Same institution · by research overlap
- Janine M Lasalle$21,917,256
- Weston Thomas Powell$230,904
- Soheil Ghiasi$437,813
- Kc Kent Lloyd$119,085,810
- Amber R Hogart$59,890
Others in their field
Other Emerging Leaders on “In Vivo”
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,216,744
- Leonard Freedmand · Leidos Biomedical Research, Inc.$66,248,714
- John Damon Chodera · Sloan-Kettering Inst Can Research$43,427,103
- Tony Moody · Duke University$34,777,314
- Alan D. Palkowitz · Indiana University Indianapolis$18,925,366
Research focus
In VivoCellsIn VitroDesignRegenerativeMechanicsExperimental StudyFetalChildAnimalsEngineeringNeuroprotectionExtracellular VesiclesNeuronsNovel TherapeuticsNeurodegenerative DisordersMolecularBirthNovel StrategiesMesenchymalDefectIntestinesIn UteroCaring
Grant awards (29)
In utero treatment of Dup15q syndrome via lipid nanoparticle based gene editing$654,339
R01 · FY2025 · NS · contact PI
Homogenized, engineered extracellular vesicles for intracranial targeting$621,989
R01 · FY2025 · EB
Bottom-up, high-throughput prototyping of extracellular vesicle mimetics using cell-free synthetic biology$574,350
R01 · FY2025 · EB
Engineering an extracellular vesicle-based targeted regenerative nanotherapeutic for multiple sclerosis$473,938
R01 · FY2025 · NS · contact PI
Bottom-up, high-throughput prototyping of extracellular vesicle mimetics using cell-free synthetic biology$91,988
R01 · FY2025 · EB
Homogenized, engineered extracellular vesicles for intracranial targeting$589,733
R01 · FY2024 · EB
Bottom-up, high-throughput prototyping of extracellular vesicle mimetics using cell-free synthetic biology$561,799
R01 · FY2024 · EB
Engineered Neuroprotective Stem-Cell Exosomes for In Utero Spina Bifida Therapy$482,120
R01 · FY2024 · NS
Engineering an extracellular vesicle-based targeted regenerative nanotherapeutic for multiple sclerosis$478,417
R01 · FY2024 · NS · contact PI
Homogenized, engineered extracellular vesicles for intracranial targeting$82,990
R01 · FY2024 · EB
Bottom-up, high-throughput prototyping of extracellular vesicle mimetics using cell-free synthetic biology$45,994
R01 · FY2024 · EB
Bottom-up, high-throughput prototyping of extracellular vesicle mimetics using cell-free synthetic biology$570,556
R01 · FY2023 · EB
Homogenized, engineered extracellular vesicles for intracranial targeting$533,627
R01 · FY2023 · EB
Engineered Neuroprotective Stem-Cell Exosomes for In Utero Spina Bifida Therapy$507,395
R01 · FY2023 · NS
Nanoparticle-mediated delivery of a base editor for in utero treatment of Canavan Disease$423,939
R21 · FY2023 · NS · contact PI
Biodegradable elastic patches for congenital diaphragmatic hernia treatment$194,375
R21 · FY2023 · HD
Engineered Neuroprotective Stem-Cell Exosomes for In Utero Spina Bifida Therapy$492,615
R01 · FY2022 · NS
Biodegradable elastic patches for congenital diaphragmatic hernia treatment$246,750
R21 · FY2022 · HD
Engineered neuroprotective stem-cell exosomes for in utero spina bifida therapy$489,939
R01 · FY2021 · NS
Fetal Tissue Engineering to Treat Spina Bifida Before Birth$343,438
R01 · FY2021 · NS · contact PI
Validation of Transabdominal Fetal Pulse Oximetry in Hypoxic Fetal Lamb Models$186,659
R21 · FY2021 · HD
Engineered neuroprotective stem-cell exosomes for in utero spina bifida therapy$499,899
R01 · FY2020 · NS
Fetal Tissue Engineering to Treat Spina Bifida Before Birth$343,438
R01 · FY2020 · NS · contact PI
Validation of Transabdominal Fetal Pulse Oximetry in Hypoxic Fetal Lamb Models$226,781
R21 · FY2020 · HD
Fetal Tissue Engineering to Treat Spina Bifida Before Birth$343,438
R01 · FY2019 · NS · contact PI
Fetal Tissue Engineering to Treat Spina Bifida Before Birth$343,438
R01 · FY2018 · NS · contact PI
Guinea pigs as a model of in utero stem cell therapy for spina bifida$78,500
R03 · FY2018 · HD · contact PI
Fetal Tissue Engineering to Treat Spina Bifida Before Birth$343,438
R01 · FY2017 · NS · contact PI
Guinea pigs as a model of in utero stem cell therapy for spina bifida$78,500
R03 · FY2017 · HD · contact PI